Vaccine group funds cervical cancer immunisations for poor

LONDON Mon Feb 4, 2013 7:55am IST

Related Topics

Stocks

   

LONDON (Reuters) - The GAVI global vaccines group is to help protect more than 180,000 girls in eight countries across Africa and Asia from cervical cancer by funding immunisation projects with vaccines from Merck (MRK.N) and GlaxoSmithKline (GSK.L).

The non-profit GAVI Alliance, which funds bulk-buy vaccination programmes for poor nations, said on Monday that Ghana, Kenya, Laos, Madagascar, Malawi, Niger, Sierra Leone and Tanzania would be the first countries to get its support for cervical cancer protection pilot projects.

Merck's Gardasil and GSK's Cervarix vaccines are the world's only two approved shots designed to protect against the sexually transmitted human papillomavirus (HPV) that causes the vast majority of cervical cancer cases.

More than 85 percent of cervical cancer deaths occur in developing nations and 275,000 women die of the disease each year. This means cervical cancer now kills more women worldwide than childbirth, claiming a life every two minutes, GAVI said.

Experts say the annual worldwide cervical cancer death rate could rise to 430,000 by 2030 if no action is taken to protect more women from it.

"Introducing the HPV vaccine in developing countries is the start of a global effort to protect all girls against cervical cancer," GAVI chief executive Seth Berkley said in a statement.

A study published in 2011 found that since 1980 new cervical cancer case numbers and deaths have dropped substantially in rich countries - many of which have screening programmes and have also recently introduced HPV vaccinations - but risen dramatically in Africa and other poor regions.

PRICE NEGOTIATIONS

GAVI - backed by the Bill & Melinda Gates Foundation, the World Health Organization, the World Bank, UNICEF, donor governments and others - has been working with the vaccine manufacturers to secure the most affordable price for the shots.

Merck has said it is prepared to offer Gardasil to GAVI countries at a deeply discounted price of $5 per dose, meaning a three-dose course would cost $15. GAVI has previously described this as a "a good starting offer".

The pilot projects are designed to give countries a chance to test whether they can put in place the systems needed to roll out HPV vaccines nationally.

Unlike most other vaccines, which are given to babies and children under age five, HPV vaccines are designed to be given to girls aged nine to 13 in an effort to protect them before they are likely to become sexually active.

One major challenge to effectively delivering HPV vaccines is that many developing countries do not offer routine health services for girls in this age group. But GAVI said initial experience in offering HPV vaccines through schools in Africa, Asia and Latin America had been encouraging.

By 2015, GAVI says it hopes to help more than 20 countries immunise around a million girls with HPV vaccines through pilot projects, and by 2020 it hopes to have helped more than 30 million girls in over 40 countries to get the vaccine.

(Editing by Stephen Powell)

FILED UNDER:

World Wrap

Reuters Showcase

Stake Sale

Stake Sale

Strong demand for Coal India boosts privatisation drive.  Full Article 

Pharma Deal

Pharma Deal

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy  Full Article 

SpiceJet Bailout

SpiceJet Bailout

SpiceJet board approves up to $243 mln share sale plan  Full Article 

AirAsia Jet Crash

AirAsia Jet Crash

AirAsia captain left seat before jet lost control - sources  Full Article 

India Art Fair

India Art Fair

Art fair turns India's capital into art hub.  Full Article 

Romney Opts Out

Romney Opts Out

Republican Romney opts out of 2016 run for president.  Full Article 

Movie Review

Movie Review

"Rahasya" is an ode to Agatha Christie.  Full Article 

Safety Concerns

Safety Concerns

Aviation leaders seek new safety mandate after deadly 2014.  Full Article 

Movie Review: Hawaizaada

Movie Review: Hawaizaada

Movie Review: Hawaizaada  Full Article | Related Story 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage